Patent Term Extensions and Filings for Regulatory Exclusivity Periods. Company shall advise Amgen in advance when it is considering any patent term extension or supplementary protection certificates or their equivalents for the Licensed Patents. With respect to any patent listings required for any Regulatory Exclusivity for Products in the Territory, the Parties shall mutually agree on which Licensed Patents to list.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. (a) AKERO will advise AMGEN when it is considering any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. (a) Erasca will advise Katmai if it desires to pursue any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. RBNC will advise AMGEN when it is considering any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents, Program Patents or Joint Patents. With respect to any patent listings required for any Regulatory Exclusivity for the Products, the Parties will discuss in good faith which Licensed Patents, Joint Patents or Program Patents, if any, to list; provided, the decision as to which Patents are listed resides with RBNC.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. Company shall advise Amgen in advance when it is considering any patent term extension or supplementary protection certificates or their equivalents for the Licensed Patents. Upon Amgen’s request, Company shall provide reasonable cooperation and assistance to Amgen (and/or its licensees) with respect to the preparation and filing of any patent term extension or supplementary protection certificates or their equivalents for the Product in Japan, With respect to any patent listings required for any Regulatory Exclusivity for the Product in the Territory, the Parties shall mutually agree on which Licensed Patents to list.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. (i) Xxxxx will consult with Clovis when considering any patent term restoration or supplemental protection certificates or their equivalent for the Subject Patents. In the event that any election with respect to patent term restoration or supplemental protection certificates or their equivalent for any Subject Patent is available, Xxxxx will decide on whether or not to make any such election, provided that Clovis will have the right to decide whether or not to make any such election with respect to any Specific Patents.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. (a) XXXXX will advise ONYX when it is considering to file and of any mandatory deadlines with respect to any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. Erasca will in its sole discretion determine whether to seek patent term extension or supplementary protection certificates or their equivalent for the Erasca Responsible Patents, in the jurisdictions where such protections are available. Erasca will keep Novartis informed regarding their plans and timelines in seeking such protections with respect to Category A Licensed Patents. Erasca shall have sole responsibility and authority regarding which Erasca Responsible Patents to list on any patent listings required for any Regulatory Exclusivity for Erasca Responsible Patents or any patent term extensions or supplementary protection certificates or their equivalent for the Erasca Responsible Patents.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. Novartis will in its sole discretion determine whether to seek patent term extension or supplementary protection certificates or their equivalent for the Novartis Responsible Patents, in the jurisdictions where such protections are available. Novartis will keep Xxxxxx informed regarding their plans and timelines in seeking such protections with respect to Category B Licensed Patents. Novartis shall have sole responsibility and authority regarding which Novartis Responsible Patents to list on any patent listings required for any Regulatory Exclusivity for Novartis Responsible Patents or any patent term extension or supplementary protection certificates or their equivalent for the Novartis Responsible Patents.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. The Parties shall cooperate in obtaining patent term restoration, supplemental protection certificates or their equivalents, and patent term extensions with respect to the Licensed Patents and Joint Patents in any Region in the Territory where applicable (each, a “Patent Term Extension”). Everest shall file for Patent Term Extensions at Everest’s sole cost and expense, subject to the following terms and conditions:
